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Background
Atypical antipsychotic medicines are highly advanced
compared to older classical antipsychotic factors. How-
ever, newer factors have been recently associated with
other side effects, such as hyperglycemia, diabetes,
increase of the body's weight and abnormal levels of lip-
ids.
Even more alarming, due to high death risks, were numer-
ous reports from patients, who were under treatment with
Clozapine or Olanzapine. These patients developed dia-
betic cetoxin soon after starting taking these medicines.
The aim of this essay is to prove whether atypical antipsy-
chotics are associated with the appearance of diabetes,
increase of the body's weight and abnormal levels of lip-
ids, or not.
Materials and methods
102 patients have been studied. They were treated with
atypical antipsychotics and they had normal weight,
blood diabetes level, and serum lipids, at the beginning of
their treatment. They suffered either from Schizophrenia
mostly, or from Bipolar Emotional Disorder. These
patients were taking Risperidone, Olanzapine, Clozapine,
Quetiapine, Amisoulpiride, Ziprasidone and Aripripa-
zole.
Six months after the beginning of the treatment with these
particular antipsychotics, the patients' weight, their diabe-
tes level and the number of their serum lipids were meas-
ured.
Results
12 of the patients had symptoms concerning their blood
diabetes. It was at a higher level. 6 of them were taking
Clozapine, 4 of them Olanzapine, one aripripazole and
one Risperidone. 37 other patients gained weight, 22 of
which were taking Olanzapine, 9 Clozapine, 5 Risperi-
done, and one Quetiapine. 22 other patients had an
increase at their serum lipids' level. 11 of them were tak-
ing Olanzapine, 5 Clozapine, 4 Risperidone, one Quetiap-
ine and one Amisoulpiride.
Conclusions
It seems that almost all atypical antipsychotics and mostly
Clozapine and Olanzapine can cause increase of the
blood diabetes level, of the weight and of total serum lip-
ids level.
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